DXCM — DexCom, Inc.

Summary of DexCom (DXCM) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 2025 revenue reached $1.21 billion, a 22% increase from $994 million in Q3 2024. Organic revenue growth was 20%.
• U.S. Revenue: Increased to $852 million (up 21% YoY), driven by growth in type 2 diabetes customer starts.
• International Revenue: Grew 22% to $357.4 million, with organic growth of 18%.
• Gross Profit: $741.3 million, representing a gross margin of 61.3%, down from 63.0% YoY.
• Operating Income: $272.9 million (22.6% of revenue), up from $212 million (21.3% of revenue) YoY.
• Net Income: $242.5 million, or $0.61 per share, marking the highest quarterly EPS in company history.
• Cash Position: Closed the quarter with over $3.3 billion in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Customer Base Expansion: Significant growth in type 2 diabetes coverage, now reaching nearly 6 million non-insulin lives in the U.S. with ongoing efforts to cover the entire 25 million type 2 population.
• Product Innovations: Introduction of DexCom Smart Basal, aimed at improving basal insulin management for type 2 users. The G7 15-day system is in limited launch with plans for broader rollout.
• Stelo Performance: Stelo surpassed $100 million in revenue within its first year, with plans for international expansion.
• Supply Chain Improvements: Stabilized global sensor supply and reduced reliance on expedited shipping, transitioning back to cost-efficient ocean freight.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $4.630 billion - $4.650 billion for the year, reflecting approximately 15% growth.
• Gross Margin Guidance: Lowered to approximately 61% due to scrap dynamics.
• Operating Margin and EBITDA Margin Guidance: Operating margin expected to be 20%-21%, with adjusted EBITDA margin at 29%-30%.
• 2026 Outlook: Base case growth expected to be in the double-digit range, with potential for outperformance depending on expanded access and innovation pipeline.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressure: Decline in gross margin attributed to higher scrap rates and increased shipping costs, although improvements are expected moving forward.
• Customer Experience Issues: Some deployment challenges with G7 sensors earlier in the year led to increased complaints, potentially impacting new customer starts. However, management believes these issues are being resolved.
• Market Competition: Concerns about competitive dynamics, particularly with Abbott's upcoming dual-analyte product, could impact market share and growth.

5. Notable Q&A Insights

• Patient Starts: Despite some challenges, Q3 saw hundreds of thousands of new customer starts, with expectations to return to record levels in Q4.
• Utilization Rates: High utilization rates observed among type 1 and type 2 intensive insulin users, with ongoing efforts to increase adoption among basal and non-insulin users.
• Market Dynamics: Management emphasized the importance of adapting marketing strategies to target new patient demographics effectively.
• G7 Transition: Transition from G6 to G7 is ongoing, with management confident in the product's performance and customer satisfaction.
• Future Innovations: Plans for an investor event to discuss future product developments, including the G8 platform, are in place, indicating a commitment to continuous innovation.

Overall, DexCom reported strong financial performance in Q3 2025, with significant growth in revenue and strategic initiatives aimed at expanding market access and enhancing customer experience. However, challenges related to gross margin and competition remain key concerns as the company looks ahead to 2026.